Denmark-based allergy specialist ALK Abello (ALKB: DC) has received Canadian approval for its house dust mite (HDM) sublingual allergy immunotherapy tablet (SLIT), Acarizax.
This takes the number of countries where Acarizax is approved to 18, and it has been launched in nine of these. Registration reviews are underway in a further eight countries and submissions are planned for elsewhere too.
HDM allergies affect more than 200 million people worldwide. The condition appears early in life and is present all year round.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze